[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Medical Center, Kazakhstan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100547621","phase-4-effectiveness-of-weight-loss-methods-on-lifespan-for-metabolic-syndrome-100547621",false,"NCT06410352","Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome","Effectiveness of Pharmacologic, Surgical, and Dietetic Weight Loss Methods on Lifespan in Patients With Metabolic Syndrome: a Comparative Clinical Trial","Inclusion Criteria:\n\n* written informed consent;\n* T2D≥3-year with glucose lowering therapy including insulin;\n* 35-55 years old;\n* BMI≥27 kg\u002Fm2 for both sex, for Asian ethnicity;\n* ongoing treatment with antihypertensive treatment;\n* weight loss 15-20% at baseline and dynamic follow-up up to 24 weeks.\n\nExclusion Criteria:\n\n* T1D;\n* \\\u003C34 age \\>56 years old;\n* unstable cardiac disorders (New York Heart Association class IV heart failure, refractory angina, uncontrolled arrhythmias, critical valvular heart disease, or severe uncontrolled hypertension);\n* glomerular filtration rate \\\u003C30 mL\u002Fmin and\u002For dialysis within 14 days before screening; • malignancy within the past 5 years;\n* gestation or lactation;\n* hereditary diseases;\n* known hypersensitivity to any of the test substances.","ALL","35 Years","65 Years",{"count":20,"type":21},220,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Background. The prevalence of type 2 diabetes mellitus (T2D) in the world is constantly increasing. Treatment of T2D is complicated by arterial hypertension and obesity (metabolic syndrome - MS). Cardiovascular complications are the main cause of death in patients with MS. Objective weight loss improves clinical and laboratory parameters in patients with T2D and hypertension.\n\nPurpose: To study lifespan, glycemic and lipid metabolism, quality of life, and cost-effectiveness of pharmacologic, surgical, and dietetic weight loss methods in obese patients with MS at 24 weeks in a comparative clinical trial.\n\nMethods:\n\n1. st stage - Study design: An open pilot prospective clinical trial. The study included 71 adult patients with T2D and hypertension for the Ramadan fast's (RF) weight loss.\n2. nd stage - Study design: A 24-week open label, prospective, multicenter, comparative clinical trial with the intention-to-treat analysis.\n\nParticipants. Totally 150 adult patients with MS aged 35-65 years and with BMI≥27 kg\u002Fm2 for Asian will be included. They will be distributed in three comparative groups: drug treatment, surgery and diet.\n\nPrimary endpoints: weight loss, fasting blood glucose, blood insulin level, systolic\u002Fdiastolic BP.\n\nSecondary endpoints: blood lipids, heel bone mineral density (HBMD), and ejection fraction (EF).\n\nExpected results:\n\nA prospective multicenter clinical study will provide comparative results on life expectancy, glycemic and lipid metabolism, quality of life, cost-effectiveness of pharmacological, bariatric and dietary methods of weight loss in patients with obesity, T2D and hypertension. As a result of the research, the following will be published:\n\n1. at least three articles and\u002For reviews in peer-reviewed scientific publications indexed in the Science Citation Index Expanded of the Web Of Science database and\u002For having a Cite Score percentile in the Scopus of at least 50;\n2. at least 1 patent for an invention (including a positive decision on it).",[27],"Metabolic Syndrome",[29,30,31,32,33,34,35],"metabolic syndrome","obesity","type 2 diabetes mellitus","weight loss","telomere length","quality of life","cost effectiveness analysis","RECRUITING","2025-11-20",{"date":39,"type":40},"2025-11-26","ACTUAL",{"date":42,"type":40},"2024-03-01",{"date":44,"type":21},"2026-07-31",{"name":46,"class":47},"University Medical Center, Kazakhstan","OTHER",""]